If approved, it would be the first oral GLP-1 specifically indicated for obesity that offers efficacy comparable to injections, marking a major milestone for patients seeking needle-free options
It can also help reduce inflammation, cellular signaling, and post-procedure recovery
A phase 3 clinical trial found a high dose of tripeptide helped patients lose an average of 22.5% of their body weight, or about 52 pounds, which is better than any medication currently on the market
Currently, the most popular obesity treatment using GLP-1 analogues is the subcutaneous injection. These injections are usually given daily or weekly and require refrigeration, along with the inconvenience of having to administer the injection directly to the patient
This customization supports the personalized medicine model that PlexusDx emphasizes
Is Tirzepatide Safer Than Ozempic